| Today's Top Story |  |  | | - FDA experts: Ease restrictions on GSK's Avandia
Twenty of 26 members of an FDA advisory panel voted Thursday to relax or end restrictions on GlaxoSmithKline's diabetes drug Avandia. Several panel members expressed support for additional research into the cardiovascular risks associated with the drug, but some experts said it was unlikely funding would be available. CNN (6/6), Reuters (6/6)       - J&J investment could be a tipping point for microbiome research
Johnson & Johnson and Second Genome announced plans to collaborate on developing drugs that work on diseases such as ulcerative colitis by modifying intestinal bacteria. Second Genome, co-founded by former Pfizer innovation center president Corey Goodman, uses DNA sequencing to analyze organisms in a human stool sample, and then uses proprietary software to determine how drugs would affect the microbes. Forbes (6/5)  | Analyst brief: Axendia: Lowering the Cost of Healthcare from the Inside Out
Healthcare administrators are seeking ways to manage a mix of Clinical, Biomedical, Facilities, Engineering and Health IT assets. Learn how Healthcare Executives are leveraging an integrated Enterprise Asset Management solution to enhance patient care and improve clinical outcomes, reduce costs and ensure compliance. |
 | Company & Financial News | | | | - Calif. biotech gets $14M funding boost
A Series B funding round led by Johnson & Johnson Development has brought in $14 million for Protagonist Therapeutics, a California-based firm seeking to develop peptide treatments with biological targets previously inaccessible to small molecules drugs as well as large protein therapies. Proceeds will be put toward the firm's research and development pipeline. Xconomy/San Francisco (6/4) | Food & Agriculture | | | | | Industrial & Environmental | | | | - Calif.-based biofuel developer gets $29.9M boost
California-based Cool Planet Energy Systems generated about $29.9 million as part of a $100 million fund-raising target for the year to further development of its first biorefinery, which would use biomass and organic waste to produce renewable gasoline, said Chief Financial Officer Barry Rowan. Bloomberg (6/6) | News from BIO | | | | - Secure document sharing services optimized for life science organizations
ShareVault, a leading provider of highly secure and controlled document sharing solutions and virtual data rooms (VDR), has aligned with BIO to provide companies with significant discounted pricing and complimentary extra features. ShareVault's VDR platform is optimized for life science companies of all sizes and flexibly priced so that even small biotech companies can afford and benefit from its technology. The ShareVault solution is intended for due diligence required during bio-pharma partnering, licensing, fundraising, M&A, clinical study management or other applications that require secure sharing of documents with third parties. Learn more and sign up for a free trial.
| SmartQuote | | | |  | A truly great book should be read in youth, again in maturity and once more in old age, as a fine building should be seen by morning light, at noon and by moonlight."
--Robertson Davies,
Canadian writer, journalist and professor  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, June 06, 2013
- Wednesday, June 05, 2013
- Tuesday, June 04, 2013
- Monday, June 03, 2013
- Friday, May 31, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment